4 articles
At least nine significant funding rounds in Q1 2026 brought total BCI investment past $960 million, with capital spreading across invasive, endovascular, ultrasound, and neurostimulation modalities.
The FOCUS-AU trial will test Synchron's advanced brain-computer interface in ten MND patients across three Australian hospitals, with surgery beginning in April.
The agency's new policy ending the two-trial requirement was written for drugs, but brain implant makers watching Synchron, Neuralink, and Paradromics navigate FDA are asking whether the same logic could eventually ease their path.
Malaysia-based Gobi Partners has invested in Cortical Labs through its Dana Impak Ventures fund, joining Horizon Ventures and Synchron founder Tom Oxley in backing the biological computing startup.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.